Astria Therapeutics (NASDAQ:ATXS) Sees Unusually-High Trading Volume – Still a Buy?

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares saw unusually-high trading volume on Wednesday . Approximately 2,002,076 shares traded hands during mid-day trading, an increase of 166% from the previous session’s volume of 753,679 shares.The stock last traded at $12.7850 and had previously closed at $12.60.

Analyst Ratings Changes

Several research firms have commented on ATXS. Citigroup reissued an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a report on Wednesday, October 8th. HC Wainwright lowered Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Oppenheimer cut Astria Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Finally, Evercore ISI reiterated an “outperform” rating and set a $26.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.50.

Astria Therapeutics Price Performance

The business has a fifty day moving average of $11.33 and a 200 day moving average of $7.98. The stock has a market cap of $748.89 million, a PE ratio of -6.13 and a beta of 0.07.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to the consensus estimate of $10.67 million. On average, equities research analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its position in shares of Astria Therapeutics by 10,311.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 3,506 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,557 shares during the last quarter. Brooklyn Investment Group grew its position in shares of Astria Therapeutics by 1,079.6% in the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 7,957 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of Astria Therapeutics by 100.9% in the 1st quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 7,139 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Astria Therapeutics during the 3rd quarter valued at approximately $98,000. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.